Phase 2 Study of ATH434 in MSA - α-Synuclein Aggregation, Imaging Biomarkers, and Severity
2:33
Phase 2 Study of ATH434 in MSA - α-Synuclein Aggregation, Imaging Biomarkers, and Severity
245 views5 months ago
YouTubeInternational Parkinson and Movement Disorde…
Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy
14:25
Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy
392 viewsOct 18, 2024
YouTubeNeurologyLive
IHL-42X Performs in Phase 2 RePOSA Study, ATH434 Eyes Phase 3 Multiple System Atrophy Trial, 4-Year Data on Lecanemab Unveiled | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
IHL-42X Performs in Phase 2 RePOSA Study, ATH434 Eyes Phase 3 Multiple System Atrophy Trial, 4-Year Data on Lecanemab Unveiled | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
9 months ago
neurologylive.com
Alterity Therapeutics Says ATH434 Showed Slowing of Clinical Progression in Phase 2 Multiple System Atrophy Study; Shares Up
Alterity Therapeutics Says ATH434 Showed Slowing of Clinical Progression in Phase 2 Multiple System Atrophy Study; Shares Up
Jan 30, 2025
marketscreener.com
ATH434 AS A POTENTIAL TREATMENT FOR MULTIPLE SYSTEM ATROPHY
9:25
ATH434 AS A POTENTIAL TREATMENT FOR MULTIPLE SYSTEM ATROPHY
114 views8 months ago
YouTubeMSA Crusaders
💰 Alterity Therapeutics Secures $20M to Drive ATH434 Development! 🔬
0:29
💰 Alterity Therapeutics Secures $20M to Drive ATH434 Development! 🔬
7 views7 months ago
YouTubeColitco
聚焦 2025：MSA 靶向药 ATH434 延缓病情 48%，降铁疗法成罕见病治疗新方向
0:43
聚焦 2025：MSA 靶向药 ATH434 延缓病情 48%，降铁疗法成罕见病治疗新方向
32 views5 months ago
bilibili兔儿777
Potential Promise Behind ATH434 for Multiple System Atrophy: Daniel Claassen, MD, MS | NeurologyLive - Clinical Neurology News and Neurology Expert Insights
Oct 2, 2024
neurologylive.com
Alterity Therapeutics présente des résultats positifs de l'essai de phase 2 d'ATH434 lors du Congrès international 2025 sur la maladie de Parkinson et les troubles du mouvement
6 months ago
zonebourse.com
0:12
ATH434 Fast Track Designation by FDA for Multiple System Atrophy Treatment
202 views11 months ago
YouTubeMCQ Pedia
16:06
“What’s Really Happening in MSA Clinical Trials—And What the Results Mean”
7.1K views8 months ago
YouTubeMultiple System Atrophy - Helping Others
Alterity presents positive phase II ATH434 data
6 months ago
theaustralian.com.au
Alterity Therapeutics Announces Granting Of U.S. FDA Fast Track Designation For ATH434
1 year ago
marketscreener.com
0:52
2025 多系统萎缩 MSA 治疗全景观察：前沿技术与临床实践双向赋能
5 months ago
bilibili兔儿777
0:52
深度解读 2025 MSA 治疗革新：从神经营养策略到细胞疗法，研发全景透视
5 months ago
bilibili兔儿777
0:43
深度解码 2025 MSA 研发热潮：从铁螯合剂到神经细胞疗法，特效方案离患者有多远？
81 views5 months ago
bilibili兔儿777
1:02
2025 多系统萎缩 MSA 靶向研发冲刺：机制探索与临床验证双线并进
18 views5 months ago
bilibili兔儿777
2025 MSA 患者新曙光：“成都造” 创新药进入临床，神经重建疗法冲刺应用
0:52
2025 MSA 患者新曙光：“成都造” 创新药进入临床，神经重建疗法冲刺应用
1 views5 months ago
bilibili兔儿777
1:22
探秘 2025：多系统萎缩 MSA 罕见病特效药，全新技术如何破解治疗困局？
10 views5 months ago
bilibili兔儿777
43:19
AtCoder Contest 434 solutions
342 views5 months ago
YouTubePraveen Seervi
5:14:32
2023 MSA Research Symposium
833 viewsJan 26, 2023
YouTubeUCL QS IoN
1:04
解码 2025：多系统萎缩 MSA 特效药全新机制与靶点，如何破解治疗困局？
8 views5 months ago
bilibili兔儿777
2025 罕见病新章：小脑萎缩靶向疗法多国协同研发，改写 “无药可医” 困局
0:51
2025 罕见病新章：小脑萎缩靶向疗法多国协同研发，改写 “无药可医” 困局
2 views5 months ago
bilibili兔儿777
1:27
2025 年多系统萎缩 MSA 靶向研发全景扫描：从实验室到临床招募，冲刺进行时
19 views5 months ago
bilibili兔儿777
不一樣的未來：治療神經退行性疾病 - Alterity Therapeutics在GCFF醫療大會上演講 (2022年6月16日)
3.5K viewsJun 18, 2022
YouTubeNAI500andGCFF
1:08
2025 多系统萎缩 MSA 靶向冲刺：全球管线加速，临床数据陆续披露
19 views5 months ago
bilibili兔儿777
36:12
LIVE: Understanding Mild Oropharyngeal Dysphagia
6.4K views6 months ago
YouTubeMultiple System Atrophy - Helping Others
0:38
2025 MSA 患者新曙光：首款细胞治疗药全国招募，多款特效药获快速通道认定
79 views5 months ago
bilibili兔儿777
30:45
Alterity Therapeutics (ASX: ATH) Presentation | NWR Virtual Healthcare Conference
1 month ago
YouTubeNWR Communications
8:15
05 IC434_H通道处理
275 views3 months ago
bilibili星象巫师
See more